FilingSEC EDGAR8-K
Moleculin Biotech Completes Part A Dosing in Pivotal Phase 2/3 R/R AML Trial
· SEC accepted
StagePhase 2/3
Filing content
The company has completed dosing for Part A of its pivotal Phase 2/3 MIRACLE trial for R/R AML and expects to report comprehensive data in the first quarter of 2027.
AI summary of the filing. Please also check the source.Related companies
Analyzed by WAPE AI.
Preparing English content…
Comments —
Loading comments…